Kingswood Wealth Advisors
KRYS icon

Kingswood Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

Kingswood Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Sell
926
-464
-33% -$139K 0.01% 727
2026
Q1 		$359K Buy
+1,390
New +$370K 0.02% 655

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kingswood Wealth Advisors's KRYS Position: Q2 2026 in Review

Kingswood Wealth Advisors reduced its Krystal Biotech (KRYS) stake by 33% in Q2 2026, selling an estimated $139K and leaving 926 shares worth $344K. The position accounts for 0.01% of the portfolio, ranked #727.

Kingswood Wealth Advisors first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $359K in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Kingswood Wealth Advisors held 926 shares of Krystal Biotech worth $344K as of Q2 2026.
  • Kingswood Wealth Advisors sold 464 Krystal Biotech shares in Q2 2026, an estimated $139K.
  • Krystal Biotech made up 0.01% of Kingswood Wealth Advisors's portfolio in Q2 2026, its #727 holding.
  • Kingswood Wealth Advisors first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • Kingswood Wealth Advisors's Krystal Biotech position peaked at $359K in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Kingswood Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.